TW200603838A - Extended release biodegradable ocular implants - Google Patents

Extended release biodegradable ocular implants

Info

Publication number
TW200603838A
TW200603838A TW094113990A TW94113990A TW200603838A TW 200603838 A TW200603838 A TW 200603838A TW 094113990 A TW094113990 A TW 094113990A TW 94113990 A TW94113990 A TW 94113990A TW 200603838 A TW200603838 A TW 200603838A
Authority
TW
Taiwan
Prior art keywords
extended release
ocular implants
release biodegradable
biodegradable ocular
implants
Prior art date
Application number
TW094113990A
Other languages
English (en)
Inventor
Jian-Guo Shia
Qing Lin
Thierry Nivaggioli
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200603838(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of TW200603838A publication Critical patent/TW200603838A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW094113990A 2004-04-30 2005-04-29 Extended release biodegradable ocular implants TW200603838A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/837,355 US8685435B2 (en) 2004-04-30 2004-04-30 Extended release biodegradable ocular implants

Publications (1)

Publication Number Publication Date
TW200603838A true TW200603838A (en) 2006-02-01

Family

ID=34966124

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094113990A TW200603838A (en) 2004-04-30 2005-04-29 Extended release biodegradable ocular implants

Country Status (10)

Country Link
US (6) US8685435B2 (zh)
EP (2) EP2777693A1 (zh)
JP (4) JP5128274B2 (zh)
AR (1) AR048773A1 (zh)
AU (1) AU2005244195B2 (zh)
BR (1) BRPI0509332A (zh)
CA (1) CA2565329C (zh)
ES (1) ES2501942T3 (zh)
TW (1) TW200603838A (zh)
WO (1) WO2005110362A1 (zh)

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
JP2004514702A (ja) 2000-11-29 2004-05-20 オキュレックス　ファーマシューティカルズ，　インコーポレイテッド 眼における移植拒絶を予防するための眼内インプラント
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
AU2005325213B2 (en) 2004-08-04 2010-10-07 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
AU2012216644B2 (en) * 2004-08-13 2014-04-10 Allergan, Inc. Ocular implant made by a double extrusion process
AU2014201844B2 (en) * 2004-08-13 2016-06-16 Allergan, Inc Ocular implant made by a double extrusion process
AU2016228285B2 (en) * 2004-08-13 2018-06-28 Allergan, Inc. Ocular implant made by a double extrusion process
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
JP5122460B2 (ja) 2005-09-16 2013-01-16 アラーガン、インコーポレイテッド 治療薬の眼内輸送のための組成物および方法
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
WO2007130134A2 (en) * 2005-12-02 2007-11-15 (Osi) Eyetech, Inc. Controlled release microparticles
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
MX2008012683A (es) 2006-04-06 2009-01-07 Nupathe Inc Implantes para el tratamiento de estados asociados con dopamina.
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
WO2008021729A2 (en) * 2006-08-07 2008-02-21 Bausch & Lomb Incorporated Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases
EP2068828A2 (en) * 2006-09-29 2009-06-17 SurModics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
US20080103368A1 (en) * 2006-10-17 2008-05-01 Ari Craine Methods, devices, and computer program products for detecting syndromes
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2008119500A1 (en) * 2007-03-30 2008-10-09 Fovea Pharmaceuticals Sa Methods for treating neovascular ocular diseases
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
US9125807B2 (en) * 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
JP2011513002A (ja) 2008-03-05 2011-04-28 イバンティス インコーポレイテッド 緑内障を治療する方法及び器具
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US9610243B2 (en) 2008-04-18 2017-04-04 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
US8946277B2 (en) * 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US8557273B2 (en) * 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
EP2276439A4 (en) 2008-05-12 2013-11-27 Univ Utah Res Found INTRAOCULAR DRUG DELIVERY DEVICE AND ASSOCIATED METHODS
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10588855B2 (en) 2008-05-12 2020-03-17 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
AU2009313203B2 (en) 2008-11-10 2015-08-27 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20120232649A1 (en) 2008-11-20 2012-09-13 Insight Innovations, Llc Intraocular Lens Cell Migration Inhibition System
HUE031062T2 (en) * 2008-11-20 2017-06-28 Insight Innovations Llc Biocompatible biodegradable intraocular implant system
US8551167B2 (en) 2008-11-20 2013-10-08 Insight Innovations, Llc Intraocular implant cell migration inhibition system
US9943402B2 (en) 2008-11-20 2018-04-17 Insight Innovations, Llc Micropatterned intraocular implant
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
AU2010213612B2 (en) 2009-02-12 2015-04-30 Incept, Llc Drug delivery through hydrogel plugs
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
KR20110122846A (ko) 2009-02-24 2011-11-11 알렉시온 파마슈티칼스, 인코포레이티드 치료용 ｔｐｏ/ｅｐｏ 모방 펩티드를 포함하는 항체
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US20100278897A1 (en) * 2009-05-01 2010-11-04 Allergan, Inc. Intraocular bioactive agent delivery system with molecular partitioning system
WO2012071476A2 (en) * 2010-11-24 2012-05-31 David Haffner Drug eluting ocular implant
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US20100314162A1 (en) * 2009-06-10 2010-12-16 Ppg Industries Ohio, Inc. Microporous material derived from renewable polymers and articles prepared therefrom
CN102597005A (zh) 2009-06-23 2012-07-18 阿雷克森制药公司 与补体蛋白质结合的双特异性抗体
JP5635605B2 (ja) 2009-07-09 2014-12-03 イバンティス インコーポレイテッド 眼内インプラント及び眼内インプラントを眼球内に送出するための方法
EP2451375B1 (en) 2009-07-09 2018-10-03 Ivantis, Inc. Single operator device for delivering an ocular implant
RU2012115120A (ru) * 2009-09-17 2013-10-27 Евоник Дегусса Корпорейшн Имплантируемые устройства, которые отличаются профилем высвобождения, и способы их изготовления и применения
BR112012011585A2 (pt) * 2009-11-02 2015-10-13 Nupathe Inc métodos para tratamento de doença de parkinson
WO2011057129A2 (en) 2009-11-09 2011-05-12 Allergan, Inc. Compositions and methods for stimulating hair growth
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
AU2011245117B2 (en) 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
EP2595602B1 (en) 2010-07-21 2018-05-23 Allergan, Inc. SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY
PT2600930T (pt) 2010-08-05 2021-03-22 Forsight Vision4 Inc Aparelho injetor e método para distribuição de fármacos
CN103153316B (zh) 2010-08-05 2015-08-19 弗赛特影像4股份有限公司 组合药物递送方法和设备
EP2600812B1 (en) 2010-08-05 2021-09-22 ForSight Vision4, Inc. Apparatus to treat an eye
BR112013009205A2 (pt) 2010-10-15 2016-07-26 Iscience Interventional Corp dispositivo para colocação na esclera de um olho, método para acessar o espaço supracoroidal de um olho, para acessar o espaço subretinal de um olho e para colocar um orifício dentro de um trato escleral em um olho.
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
CA2826453A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
IN2013MN02384A (zh) * 2011-06-10 2015-06-12 Ramscor Inc
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
EP2726016B1 (en) 2011-06-28 2023-07-19 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
LT2755600T (lt) 2011-09-16 2021-04-26 Forsight Vision4, Inc. Skysčio pakeitimo aparatas
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
DK2812372T3 (en) 2012-02-09 2018-11-05 Novus Int Inc HETEROATOM WITH CYCLIC DIMERS
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
AU2013290122B2 (en) 2012-07-12 2016-08-11 Novus International Inc. Matrix and layer compositions for protection of bioactives
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
ES2709351T3 (es) 2012-09-27 2019-04-16 Allergan Inc Sistemas de administración de fármacos biodegradables para la liberación sostenida de proteínas
WO2014066653A1 (en) * 2012-10-26 2014-05-01 Allergan, Inc. Ketorolac-containing sustained release intraocular drug delivery systems
WO2014066658A1 (en) * 2012-10-26 2014-05-01 Allergan, Inc. Ketorolac-containing sustained release drug delivery systems
WO2014066644A1 (en) * 2012-10-26 2014-05-01 Allergan, Inc. Ketorolac-containing sustained release drug delivery systems
EP2916827B1 (en) 2012-11-08 2020-06-10 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
US10617558B2 (en) 2012-11-28 2020-04-14 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
AU2014216112B2 (en) 2013-02-15 2019-02-21 Allergan, Inc. Sustained drug delivery implant
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US20160051673A1 (en) 2013-03-29 2016-02-25 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
US9539139B2 (en) 2013-05-03 2017-01-10 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
EP3003454B1 (en) 2013-06-03 2020-01-08 Clearside Biomedical, Inc. Apparatus for drug delivery using multiple reservoirs
EP3011345B1 (en) 2013-08-07 2017-10-04 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (ahus) biomarker proteins
JP6543431B2 (ja) * 2013-10-10 2019-07-10 ユニバーシティー オブ ユタ リサーチ ファウンデーションＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｕｔａｈ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 眼内薬物送達デバイスおよび付随する方法
PL3062775T3 (pl) 2013-10-31 2018-05-30 Allergan, Inc. Implanty wewnątrzgałkowe zawierające prostamid i sposoby ich stosowania
CA2928646C (en) * 2013-11-08 2020-05-05 Hollister Incorporated Oleophilic lubricated catheters
RU2690841C1 (ru) * 2013-11-15 2019-06-06 Аллерган, Инк. Способы лечения патологических состояний глаза с помощью имплантата с долговременной доставкой лекарственного вещества
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
WO2015184173A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2015195842A1 (en) * 2014-06-17 2015-12-23 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorders
WO2015196085A2 (en) 2014-06-20 2015-12-23 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
US10709547B2 (en) 2014-07-14 2020-07-14 Ivantis, Inc. Ocular implant delivery system and method
EP3679908A1 (en) 2014-07-15 2020-07-15 ForSight Vision4, Inc. Ocular implant delivery device
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
KR102510540B1 (ko) 2014-10-03 2023-03-16 나노틱스 엘엘씨 가용성 생물분자의 생물학적 활성을 억제하기 위한 조성물 및 방법
BR112017009660A2 (pt) 2014-11-10 2017-12-19 Forsight Vision4 Inc dispositivos de administração de fármacos expansíveis e métodos de utilização
FR3028410A1 (fr) 2014-11-18 2016-05-20 Pierre Coulon Implant capsulaire multifonctionnel
US10525034B2 (en) * 2014-12-15 2020-01-07 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of glaucoma
WO2016123454A1 (en) 2015-01-29 2016-08-04 Board Of Trustees Of Miching State University Cryptic polypeptides and uses thereof
WO2016144832A1 (en) 2015-03-06 2016-09-15 Envisia Therapeutics, Inc. Implant applicators and methods of administering implants
CA2979397A1 (en) 2015-03-12 2016-09-15 Board Of Trustees Of Michigan State University Compositions and methods for measuring c-peptide binding and diagnosing immune-mediated diseases
WO2016183183A1 (en) 2015-05-11 2016-11-17 The Johns Hopkins University Autoimmune antibodies for use in inhibiting cancer cell growth
EP4279064A3 (en) 2015-05-12 2024-02-28 Incept, LLC Drug delivery from hydrogels
CN107949354B (zh) 2015-07-22 2022-02-18 因赛普特有限责任公司 涂覆的泪点塞
EP3324944A4 (en) 2015-07-23 2019-04-03 Aerie Pharmaceuticals, Inc. INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE
ES2962607T3 (es) 2015-08-14 2024-03-20 Alcon Inc Implante ocular con sensor de presión
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
GB201519811D0 (en) * 2015-11-10 2015-12-23 Univ Belfast Ocular compositions
WO2017083779A1 (en) 2015-11-12 2017-05-18 Graybug Vision, Inc. Aggregating microparticles for therapy
EP3377009B1 (en) 2015-11-20 2020-10-28 ForSight Vision4, Inc. Porous structures for extended release drug delivery devices
US11938058B2 (en) 2015-12-15 2024-03-26 Alcon Inc. Ocular implant and delivery system
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
PT109154B (pt) * 2016-02-12 2019-11-05 Univ De Coimbra Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
JP7009384B2 (ja) 2016-04-05 2022-01-25 フォーサイト・ビジョン フォー・インコーポレーテッド 移植可能な眼薬送達デバイス
WO2017176762A1 (en) 2016-04-06 2017-10-12 Nanotics, Llc Particles comprising subparticles or nucleic acid scaffolds
CN109937025B (zh) 2016-04-20 2022-07-29 多斯医学公司 生物可吸收眼部药物的递送装置
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
CA3072847A1 (en) 2016-08-12 2018-02-15 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
AU2018240462C1 (en) 2017-03-23 2022-12-08 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
EP3621654A4 (en) 2017-05-10 2021-02-17 Graybug Vision, Inc. PROLONGED-RELEASE MICROPARTICLES AND SUSPENSIONS OF THESE INTENDED FOR MEDICAL THERAPY
JP7309624B2 (ja) 2017-06-13 2023-07-18 インフォーカス，インコーポレイテッド 緑内障の治療のためのシステム、方法及び器具
US20190062428A1 (en) 2017-06-19 2019-02-28 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
CA3069438A1 (en) 2017-07-11 2019-01-17 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
CN116271012A (zh) 2017-07-27 2023-06-23 瑞颂医药公司 高浓度抗c5抗体制剂
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
WO2019036605A2 (en) 2017-08-17 2019-02-21 Massachusetts Institute Of Technology MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
AU2018329850A1 (en) 2017-09-08 2020-04-23 Bristol-Myers Squibb Company Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH)
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
JP7314155B2 (ja) 2017-11-21 2023-07-25 フォーサイト・ビジョン４・インコーポレーテッド 膨張可能ポート送達システムのための流体交換装置及びその使用方法
MX2021015518A (es) 2018-03-14 2022-07-21 Surface Oncology Inc Anticuerpos que se unen a cd39 y sus usos.
CN112512571A (zh) 2018-03-22 2021-03-16 表面肿瘤学公司 抗il-27抗体及其用途
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
US10907161B2 (en) 2018-04-19 2021-02-02 Checkmate Pharmaceuticals, Inc. Synthetic RIG-I-like receptor agonists
US20200109195A1 (en) 2018-05-21 2020-04-09 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
US20220275043A1 (en) 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
EP3833442A2 (en) 2018-08-09 2021-06-16 Compass Therapeutics LLC Antibodies that bind cd277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
WO2020033923A1 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antigen binding agents that bind cd277 and uses thereof
CA3119161A1 (en) 2018-11-13 2020-05-22 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
AU2020208397A1 (en) 2019-01-16 2021-08-12 Compass Therapeutics Llc Formulations of antibodies that bind human CD137 and uses thereof
EP3920899A2 (en) 2019-02-08 2021-12-15 The UAB Research Foundation Immunotherapy for the treatment and prevention of inflammatory bowel disease
WO2020243608A1 (en) * 2019-05-31 2020-12-03 Dose Medical Corporation Bioerodible polyester polymer implants and related methods of use
MX2021015760A (es) 2019-06-27 2022-04-06 Layerbio Inc Sistemas de administracion de medicamentos de dispositivos oculares.
WO2021055329A1 (en) 2019-09-16 2021-03-25 Surface Oncology, Inc. Anti-cd39 antibody compositions and methods
CN115087671A (zh) 2019-09-25 2022-09-20 表面肿瘤学公司 抗il-27抗体及其用途
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
MX2022004825A (es) 2019-10-23 2022-10-10 Regeneron Pharma Agonistas sintéticos del receptor similar a rig i.
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
ES2952213T3 (es) 2020-02-06 2023-10-30 Ocular Therapeutix Inc Composiciones y métodos para tratar enfermedades oculares
BR112022018815A2 (pt) 2020-03-25 2022-11-29 Ocular Therapeutix Inc Implante ocular contendo um inibidor de tirosina cinase
US20230349887A1 (en) 2020-05-15 2023-11-02 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
KR20230042049A (ko) 2020-07-21 2023-03-27 알러간, 인코포레이티드 높은 프로스타미드 로딩을 갖는 안구내 임플란트
EP4274529A1 (en) 2021-01-11 2023-11-15 Alcon Inc. Systems and methods for viscoelastic delivery
JP2024516970A (ja) 2021-05-07 2024-04-18 サーフィス オンコロジー， エルエルシー 抗ｉｌ－２７抗体及びその使用
CA3220629A1 (en) 2021-05-28 2022-12-01 Tobin J. CAMMETT Methods for detecting cm-tma biomarkers
WO2023230116A1 (en) 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies
WO2023230128A1 (en) 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use
WO2024054436A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
WO2024086306A1 (en) * 2022-10-19 2024-04-25 Vitakey Inc. Formulated food products

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US19098A (en) * 1858-01-12 Valve arrangement for steam-engines
DE430539C (de) 1922-04-21 1926-06-23 J G Farbenindustrie Akt Ges Verfahren zur Darstellung von AEthylenchlorid
US3986510A (en) 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US3985510A (en) * 1974-05-28 1976-10-12 Taylor Fred W Flash reactor unit
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
US5286763A (en) * 1983-03-22 1994-02-15 Massachusetts Institute Of Technology Bioerodible polymers for drug delivery in bone
JPS6050051U (ja) 1983-09-14 1985-04-08 日産車体株式会社 自動車のリヤスピ−カ取付け構造
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
JPH01500034A (ja) 1986-04-10 1989-01-12 ダラテック　プロプライエタリー　リミテッド ワクチンおよび植込剤
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
JP2702729B2 (ja) 1988-02-24 1998-01-26 エーザイ株式会社 徐放性埋込剤
JPH0216917A (ja) 1988-07-05 1990-01-19 Iseki & Co Ltd 脱穀装置の拡散装置
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
WO1991015495A1 (en) 1990-04-02 1991-10-17 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US6194439B1 (en) 1991-05-29 2001-02-27 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
HUT71553A (en) 1992-08-06 1995-12-28 Warner Lambert Co 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
ATE195065T1 (de) 1993-02-26 2000-08-15 Santen Pharmaceutical Co Ltd Biologisch abbaubarer sklerastopfen
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
WO1996026716A1 (en) 1995-02-28 1996-09-06 Innapharma, Inc. Elcatonin controlled release microsphere formulation for treatment of osteoporosis
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
EP0992244A4 (en) 1997-07-02 2001-01-17 Santen Pharmaceutical Co Ltd SCLERAL PLUGS OF POLYLACTIC ACID
JPH1170138A (ja) * 1997-07-02 1999-03-16 Santen Pharmaceut Co Ltd ポリ乳酸強膜プラグ
US6306426B1 (en) 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US20040208910A1 (en) * 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
EP1550471A1 (en) 2000-11-29 2005-07-06 Allergan Inc. Intraocular implants for preventing transplant rejection in the eye
JP2004514702A (ja) 2000-11-29 2004-05-20 オキュレックス　ファーマシューティカルズ，　インコーポレイテッド 眼における移植拒絶を予防するための眼内インプラント
JP4121372B2 (ja) * 2001-02-27 2008-07-23 千寿製薬株式会社 生分解性ポリマー型薬物放出システム
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
EP1408876A4 (en) * 2001-06-22 2004-09-22 Durect Corp ZERO ORDER COAXIAL IMPLANTS WITH EXTENDED RELEASE
US6488952B1 (en) * 2001-08-28 2002-12-03 John P. Kennedy Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
AU2002351739A1 (en) 2001-12-18 2003-06-30 Novo Nordisk A/S Solid dose micro implant
US6541504B1 (en) 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
JP2005532313A (ja) 2002-05-07 2005-10-27 コントロール・デリバリー・システムズ・インコーポレイテッド 薬物送達装置の形成方法
US7090681B2 (en) 2002-09-18 2006-08-15 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US7368126B2 (en) * 2002-11-06 2008-05-06 Guohua Chen Controlled release depot formulations
US20040137059A1 (en) 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20050244466A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244500A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision

Also Published As

Publication number Publication date
JP2014133772A (ja) 2014-07-24
EP2777693A1 (en) 2014-09-17
JP5128274B2 (ja) 2013-01-23
CA2565329A1 (en) 2005-11-24
EP1740153A1 (en) 2007-01-10
EP1740153B2 (en) 2017-08-09
JP5706020B2 (ja) 2015-04-22
WO2005110362A1 (en) 2005-11-24
CA2565329C (en) 2014-10-07
US10154960B2 (en) 2018-12-18
EP1740153B1 (en) 2014-06-25
JP2012012408A (ja) 2012-01-19
US20050244467A1 (en) 2005-11-03
US20190254964A1 (en) 2019-08-22
US8895049B2 (en) 2014-11-25
JP2007535535A (ja) 2007-12-06
US8974812B2 (en) 2015-03-10
US10874605B2 (en) 2020-12-29
US8685435B2 (en) 2014-04-01
BRPI0509332A (pt) 2007-09-04
ES2501942T3 (es) 2014-10-02
JP2012207028A (ja) 2012-10-25
AR048773A1 (es) 2006-05-24
US20080241223A1 (en) 2008-10-02
JP5552102B2 (ja) 2014-07-16
US20150209276A1 (en) 2015-07-30
AU2005244195A1 (en) 2005-11-24
AU2005244195B2 (en) 2011-06-30
US20140035184A1 (en) 2014-02-06
US20140249123A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
TW200603838A (en) Extended release biodegradable ocular implants
MX2009005405A (es) Sistemas intraoculares de distribucion de farmaco.
ATE440623T1 (de) Biologisch absorbierbare überzüge für implantierbare vorrichtungen
NO20013094D0 (no) Biokompatible, okul¶re, legemiddelavgivende implantatanordninger med regulert frigivningsvirkning, ogfremgangsmåter
WO2002002076A3 (en) Methods for treating inflammation-mediated conditions of the eye
BRPI0712194A2 (pt) Implantes pélvico e cirúrgico combinação ferramenta cirúrgica útil para implantar um implante pélvico métodos de tratamento de uma condição pélvica, e de prolapso vaginal, e, método para manipular um implante cirúrgico
TW200603843A (en) Tissue enhancement implant and method
WO2007150018A3 (en) Steroid-containing sustained release intraocular implants and related methods
WO2005120400A3 (en) Methods and apparatuses for bone restoration
DE602005002745D1 (de) Medizinische vorrichtungen und verfahren zu ihrer herstellung
TW200605853A (en) Steroid-containing sustained release intraocular implants and related methods
WO2006023130A3 (en) Biodegradable controlled release bioactive agent delivery device
TW200512016A (en) Drug-coated stents and methods of use therefor
WO2009005714A3 (en) Surgical articles and methods for treating pelvic conditions
DE50210591D1 (de) Implantate mit fk506 zur restenosebehandlung und -prophylaxe
WO2009017680A3 (en) Pelvic floor treatments and related tools and implants
MX2008002552A (es) Un dispositivo y un metodo para mejorar la funcion de una valvula cardiaca.
WO2007061983A3 (en) Instrument for implanting a wrist prosthesis
IL182262A0 (en) Self-fixating scaffolds
TW200500099A (en) Sustained release device and method for ocular delivery of adrenergic agents
ATE405160T1 (de) Zusammensetzung zur behandlung von saatgut
TW200505507A (en) Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
WO2008130395A3 (en) Desferrithiocin analogue actinide decorporation agents
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
WO2009018203A3 (en) Integrated circuit formation using different angled implants